Stock Rating Downgrade
The Value Trend Rating for Xenon Pharmaceuticals Inc (NASDAQ: XENE) weakened recently from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
On 3/8/24, Xenon Pharmaceuticals Inc (NASDAQ: XENE) stock rose slightly by 0.2%, closing at $46.24. However, trading volume in this advance was unusually low at 59% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -2.0% during the last week.
Current PriceTarget Research Rating
XENE is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Xenon Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Xenon Pharmaceuticals has a very low Appreciation Score of 8 but a good Power Rating of 74, triggering the Negative Value Trend Rating.
Be the first to comment